Table 4 Best overall response—efficacy group

From: Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

 

Group A

Group B

Group C

Total

Efficacy group (patients treated at phase 2 dose)

20

10

5

35

Response rate n (%)

12 (60.0%)

6 (60.0%)

1 (20.0%)

19 (54.3%)

90% CI

39.4–78.3%

30.4–85.0%

1.0–65.7%

39.2–68.8%

Back to article page